See more : Flight Centre Travel Group Limited (FGETF) Income Statement Analysis – Financial Results
Complete financial analysis of CalciMedica, Inc. (CALC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CalciMedica, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Toami Corporation (5973.T) Income Statement Analysis – Financial Results
- Himalaya Shipping Ltd. (HSPPF) Income Statement Analysis – Financial Results
- Qingdao Port International Co., Ltd. (601298.SS) Income Statement Analysis – Financial Results
- Central Natural Resources, Inc. (CTNR) Income Statement Analysis – Financial Results
- Sun Corporation (6736.T) Income Statement Analysis – Financial Results
CalciMedica, Inc. (CALC)
About CalciMedica, Inc.
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 58.00K | 52.00K | 519.00K | 395.00K | 303.00K | 175.00K |
| Gross Profit | -58.00K | -52.00K | -519.00K | -395.00K | -303.00K | -175.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 12.36M | 14.11M | 18.90M | 20.96M | 30.58M | 22.97M |
| General & Administrative | 0.00 | 19.10M | 17.04M | 8.87M | 6.92M | 5.60M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.46M | 19.10M | 17.04M | 8.87M | 6.92M | 5.60M |
| Other Expenses | 0.00 | 2.96M | 0.00 | 2.16M | 72.00K | 0.00 |
| Operating Expenses | 21.82M | 33.22M | 35.95M | 29.83M | 37.50M | 28.57M |
| Cost & Expenses | 21.88M | 33.22M | 35.95M | 29.83M | 37.50M | 28.57M |
| Interest Income | 0.00 | 575.00K | 126.00K | 143.00K | 393.00K | 192.00K |
| Interest Expense | 0.00 | 0.00 | 126.00K | 143.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 58.00K | 52.00K | 519.00K | 395.00K | 303.00K | 175.00K |
| EBITDA | -34.19M | -7.64M | -35.30M | -27.14M | -36.73M | -28.20M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.88M | -36.18M | -35.95M | -29.83M | -37.50M | -28.57M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.48M | 28.36M | 126.00K | 2.30M | 465.00K | 192.00K |
| Income Before Tax | -34.36M | -35.61M | -35.82M | -27.53M | -37.04M | -28.38M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -109.90K | 2.39M | -2.00M | -538.00K | -393.00K | 13.86K |
| Net Income | -34.36M | -35.61M | -35.82M | -27.53M | -37.04M | -28.38M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -7.65 | -23.20 | -23.66 | -58.24 | -35.85 | -33.10 |
| EPS Diluted | -7.65 | -23.20 | -23.66 | -58.24 | -35.85 | -33.10 |
| Weighted Avg Shares Out | 4.49M | 1.53M | 1.51M | 472.75K | 1.03M | 857.28K |
| Weighted Avg Shares Out (Dil) | 4.49M | 1.53M | 1.51M | 472.75K | 1.03M | 857.28K |
CalciMedica Reports Second Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Positive topline data announced from CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); additional data to be presented at a medical meeting later this year First patient enrolled in KOURAGE, Phase 2 trial of Auxora™ in severe acute kidney...
Does CalciMedica Inc. (CALC) Have the Potential to Rally 232.3% as Wall Street Analysts Expect?
The consensus price target hints at a 232.3% upside potential for CalciMedica Inc. (CALC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an...
CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)
Development of Auxora in AKI is supported by both clinical and pre-clinical evidence Topline data expected in 2025 LA JOLLA, Calif. , July 9, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on...
CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences
LA JOLLA, Calif. , July 8, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses,...
CalciMedica Set to Join Russell Microcap® Index
LA JOLLA, Calif., July 1, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today...
CalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper-inflamed patients Statistically significant dose response with up to 61.7%...
CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
Conference call and webcast to be held tomorrow, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m.
3 Massively Undervalued 10-Bagger Stocks to Buy
If you're on the lookout for the best undervalued stocks to buy now, look no further. Savvy investors are always looking for cheap businesses with substantial growth potential.
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
Last patient enrolled in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP); topline data expected in 2Q 2024 KOURAGE, Phase 2 trial in severe acute kidney injury (AKI) remains on track to initiate patient enrollment in 2Q 2024...
CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024
Collaborators from Cedars-Sinai to present human proteomics data supporting the potential benefits of Auxora™ in severe acute pancreatitis (AP) LA JOLLA, Calif., May 7, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium...
Source: https://incomestatements.info
Category: Stock Reports